As of November 6, 2026, Keros Therapeutics, Inc. is a publicly traded company (Nasdaq: KROS); its largest reported holder is BlackRock, with 9.1% on Schedule 13G/A of October 27, 2026, then BlackRock (8.4%). The largest insider holding is Jasbir Seehra, the chief executive and a director, with 440,708 shares (2.2% of shares outstanding), per Form 4 of April 6, 2026 (Schedule 13G/A, October 27, 2026).
Is this your company?
About to sign with, pay or invest in Keros Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Keros Therapeutics, Inc. a real, registered company?
- Keros Therapeutics, Inc. files with the SEC under CIK 1664710 (its SEC filings).
- Its shares are listed under the ticker KROS on Nasdaq (SEC company record).
- business address in Lexington, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Keros Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Keith Regnante, Chief Financial Officer (Form 8-K filed 2026-07-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Keros Therapeutics, Inc.'s owners and officers?
Keros Therapeutics, Inc.: business address in Lexington, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock Portfolio Management LLC | 9.1% |
| Schedule 13G/A, 2026-07-29 | Blackrock, Inc. | 8.4% |
| Schedule 13G, 2026-07-17 | Blackrock Portfolio Management LLC | 5.7% |
| Schedule 13G, 2026-05-15 | Nantahala Capital Management, LLC | 6.9% |
| Schedule 13G, 2026-04-07 | Blackrock, Inc. | 10.1% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | D. E. Shaw & Co., L.P. | 3.9% |
| Schedule 13G/A, 2026-02-17 | Exoduspoint Capital Management, LP | 0.04% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 0% |
| Schedule 13G/A, 2026-02-17 | Madison Avenue International LP | 2.7% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 5% |
| Schedule 13G, 2025-11-18 | Exoduspoint Capital Management, LP | 6.3% |
Questions about who owns Keros Therapeutics, Inc.
Who owns Keros Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Keros Therapeutics, Inc.: Blackrock Portfolio Management LLC (9.1%, Schedule 13G/A, filed 2026-10-27), Blackrock, Inc. (8.4%, Schedule 13G/A, filed 2026-07-29) and Nantahala Capital Management, LLC (6.9%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Keros Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Keros Therapeutics, Inc. on this page are Blackrock Portfolio Management LLC (9.1%), Blackrock, Inc. (8.4%) and Nantahala Capital Management, LLC (6.9%).
When did Blackrock Portfolio Management LLC buy into Keros Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock Portfolio Management LLC on this page is the Schedule 13G, filed 2026-07-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-10-27, reports 9.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Keros Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Keros Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keros Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-22 | Keith Regnante | Chief Financial Officer | departed | 2026-08-03 |
| Form 8-K, 2026-07-22 | Annita Tanini | Controller | appointed | 2026-08-04 |
| Form 8-K, 2026-06-25 | Anne Prener | Director | appointed |
Which insiders own Keros Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 440,708 shares (2.2% of shares outstanding) (Form 4, 2026-04-06).
- , a director: 113,191 shares (0.58% of shares outstanding), 10,958 held directly and 102,233 indirectly (Form 4, 2026-06-08).
- , the chief operating officer: 60,000 shares (0.31% of shares outstanding) (Form 4, 2025-02-19).
- , the corp. controller and vice president: 45,144 shares (0.23% of shares outstanding) (Form 4, 2026-08-20).
- , a director: 45,057 shares (0.23% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-12-18).
Shares outstanding: 19,624,374 as of 2026-10-30, from the company's latest SEC cover page.
How much has Keros Therapeutics, Inc. raised?
No fundraising or offering filing from Keros Therapeutics, Inc. is on file with us.
Keep reading
More on Keros Therapeutics, Inc. and the records around it.
Keros Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jul 2026
Companies that share a holder
- ExodusPoint Capital Management, LP also filed stake reports on 3 other companies: RE/MAX Holdings, Inc. (Aug 2026), SPRUCE BIOSCIENCES, INC. (Apr 2026), ALT5 Sigma Corp (Aug 2025)
- Pontifax Management 4 GP (2015) Ltd. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), LB Pharmaceuticals Inc (Sep 2025), Climb Bio, Inc. (Sep 2025)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/keros-therapeutics